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ABSTRACT
Chemokine receptor CXCR4 is a key factor for tumor growth and metastasis 
in several types of human cancer. This study investigated the feasibility of CXCR4-
directed imaging of small cell lung cancer (SCLC) with positron emission tomography/
computed tomography (PET/CT) using the radiolabelled chemokine ligand [68Ga]
Pentixafor.
10 patients with primarily diagnosed (n=3) or pre-treated (n=7) SCLC (n=9) 
or large cell neuroendocrine carcinoma of the lung (LCNEC, n=1) underwent 
[68Ga]Pentixafor-PET/CT. 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG, n=6) and/
or somatostatin receptor (SSTR)-directed PET/CT with [68Ga]DOTATOC (n=5) and 
immunohistochemistry (n=10) served as standards of reference.
CXCR4-PET was positive in 8/10 patients and revealed more lesions with 
significantly higher tumor-to-background ratios than SSTR-PET. Two patients who were 
positive on [18F]FDG-PET were missed by CXCR4-PET, in the remainder [68Ga]Pentixafor  
detected an equal (n=2) or higher (n=2) number of lesions. CXCR4 expression of 
tumor lesions could be confirmed by immunohistochemistry.
Non-invasive imaging of CXCR4 expression in SCLC is feasible. [68Ga]Pentixafor 
as a novel PET tracer might serve as readout for confirmation of CXCR4 expression as 
prerequisite for potential CXCR4-directed treatment including receptor-radio(drug)
peptide therapy.
INTRODUCTION
Small cell lung cancer (SCLC) is a neuroendocrine 
tumor that represents 15% of all lung cancers [1]. It occurs 
predominantly in smokers as almost all patients have a 
history of tobacco use.
SCLC is distinguished clinically from most other 
types of non-small cell lung cancer by its rapid doubling 
time, high growth fraction, and the early development of 
metastases. Only one-third of patients are diagnosed with 
localized disease, and treatment strategies have focused on 
systemic therapy [2]. Although SCLC is highly responsive 
to both chemotherapy and radiotherapy, it commonly 
relapses within months despite treatment [3, 4]. Response 
rates to second-line treatments have been reported to 
range between 10-20% [5]. Thus, new treatment options 
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including personalized medicine targeting specific 
molecular markers are urgently needed.
Chemokine receptor CXCR4 has been described to 
play a pivotal role in tumor growth and progression, tumor 
invasiveness and metastasis [6]. Overexpression of the 
receptor has been reported in more than 30 different types 
of cancer, including lymphoma, breast, pancreatic, ovarian 
and lung cancer [7-10]. In SCLC, almost ubiquitous 
CXCR4 overexpression has been shown to correlate with 
negative outcome [11]. 
Recently, a radiolabelled CXCR4-ligand ([68Ga]
Pentixafor) for PET imaging has been developed [12, 
13]. Dosimetry and proof-of-concept for visualization 
of CXCR4-expression has recently been demonstrated 
in patients with hematologic malignancies [14, 15], 
glioblastoma [16] and myocardial infarction [17, 18]. 
This is the first report of non-invasive detection 
of CXCR4-expression in SCLC patients. CXCR4 may 
serve as a promising new target for both diagnostic and 




8/10 patients presented with extended disease, 2 
subjects with limited disease. Metastatic sites included 
lymph nodes (9/10), adrenals (4/10), liver (4/10), pleura 
(3/10), bone (2/10), and brain (1/10). Intrapulmonary 
metastases were detected in (3/10) subjects, 1 patient 
suffered from leptomeningeal tumor spread. All pretreated 
patients had undergone chemotherapy with cisplatin and 
etoposide. At the time point of imaging, only 2/10 patients 
were currently on treatment. Patient #2 had started 
combined radio-chemotherapy 14 days prior to [68Ga]-
Pentixafor-PET. In patient #5, chemotherapy had been 
initiated 9 days earlier.
Imaging results
[68Ga]Pentixafor-PET was visually 
positive in 8/10 patients. Interestingly, the 
only patient with LCNEC (patient #6) did not 
Figure 1: Example of a CXCR4-positive, SSTR-negative SCLC patient. Display of maximum intensity projections (upper 
row) and transaxial images (lower row) of both CXCR4- and SSTR-directed PET/CT (interval between both scans, 6 days) in a patient 
with recurrent SCLC (patient #3). Whereas [68Ga]Pentixafor-PET demonstrates intense tracer retention in various tumor manifestations 
including mediastinal lymph nodes, bone and pleural lesions, SSTR-directed PET proves negative (arrows; insert: corresponding contrast-
enhanced transaxial CT).
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demonstrate any relevant [68Ga]Pentixafor 
uptake. The negative SCLC patient (patient #2) was on 
combined radio-chemotherapy which had been initiated 14 
days prior to imaging. All other patients exhibited intense 
tracer accumulation in both primary tumor as well as 
lymph node and organ metastases. 
Patient-basis analysis
In comparison to [68Ga]DOTATOC (n = 5), 2/5 
subjects were [68Ga]Pentixafor-positive/SSTR-negative 
(Figure 1), 2/5 patients were positive and 1/5 negative in 
both scans.
In comparison to [18F]
FDG (n = 6), both [68Ga]Pentixafor 
and [18F]FDG were positive in 4/6 patients. The remaining 
two patients presented with [18F]FDG-positive/CXCR4-
negative lesions.
Lesion-basis analysis
On a lesion basis, in the 5 patients in whom 
[68Ga]DOTATOC-PET was performed, [68Ga]
Pentixafor detected a total of 55 lesions (lymph 
nodes, n = 33; liver, n = 9; pleura, n = 6; brain, n = 4; 
adrenals, n = 2; lungs, n = 1) whereas SSTR-PET 
Figure 2: Example of additional value of [68Ga]Pentixafor-PET in an SCLC patient. Display of maximum intensity projections 
(upper row) and transaxial images (lower row) of both CXCR4- and [18F]FDG-PET/CT (interval between both scans, 6 days) in a patient 
with recurrent SCLC (patient #4). [68Ga]Pentixafor-PET demonstrates more intense tracer retention in various tumor manifestations 
including mediastinal lymph nodes (arrows; insert: corresponding contrast-enhanced transaxial CT).
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depicted only 20 foci (lymph nodes, n = 14; adrenals, n 
= 2; brain, n = 2; pleura, n = 1; lungs, n = 1). The 35 
lesions exclusively visualized by [68Ga]Pentixafor 
were lymphonodal (n = 19), hepatic (n = 9), pleural (n = 
5) and CNS (n = 2) manifestations of origin; 16 of those 
were present in the two CXCR4-positive/SSTR-negative 
subjects. 
In comparison to [18F]FDG (44 lesions), CXCR4-
directed PET visualized 33 tumor manifestations. 23 foci 
were missed in the two [18F]FDG-positive/[68Ga]Pentixafor 
-negative patients. In the remaining 4 subjects, CXCR4-
PET detected 26 lymph node (vs. [18F]FDG: n = 15), 3 
adrenal (vs. [18F]FDG: n = 3), 3 lung (vs. [18F]FDG: n = 
3), and 1 liver (vs. [18F]FDG: n = 0) lesions/metastases 
(Figure 2).
On semi-quantitative analysis, the median 
SUVmean of the primary tumors was 6.9 (range, 2.6-
11.3) and the median SUVmax was 8.8 (range, 4.8-15.5). 
The corresponding SUVmean for [
68Ga]DOTATOC 
and [18F]FDG were 5.6 (range, 2.7-8.5) and 7.1 
(range, 3.1-24.6), respectively; those for SUVmax 9.1 
(range, 4.7-13.5; [68Ga]DOTATOC) and 9.9 (range, 
4.7-38.1; [18F]FDG). The respective value for the 
hottest metastatic lesion in [68Ga]Pentixafor-PET 
 were 7.5 (range, 3.0-14.1) for SUVmean and 10.0 (range, 
6.5-19.4) for SUVmax, respectively. This compared to 
9.4 (range, 8.9-9.9; [68Ga]DOTATOC) and 7.0 (range, 
3.4-15.5; [18F]FDG) for SUVmean and for SUVmax to 17.6 
(range, 16.7-18.5; [68Ga]DOTATOC) and 11.2 (range, 
4.9-19.3; [18F]FDG). Tumor-to-background ratios were 
significantly higher for [68Ga]Pentixafor than for [68Ga]
DOTATOC regarding the primary tumor as well as the 
hottest metastatic lesion with a median P/Bmean of 5.4 
(range, 1.3-7.5) vs. 0.7 (range, 0.3-1.0) and a median P/Bmax 
of 3.7 (range, 1.8-5.1) vs. 0.7 (range, 0.4-1.0). Median M/
Bmean ratios were 5.5 (range, 2.4-12.9) vs. 1.2 (range, 1.1-
1.2) and median M/Bmax ratios were 3.2 (range, 2.4-8.3) vs. 
1.5 (range, 1.3-1.6), respectively. [68Ga]Pentixafor ratios 
were comparable to [18F]FDG (median P/Bmean, 3.0; range, 
1.4-8.6; median P/Bmax, 3.2; range, 1.4-8.7; median M/
Bmean, 4.1; range, 1.5-6.7; median M/Bmax, 3.5; range, 1.5-
8.6). The individual SUV and tumor-to-background values 
for CXCR4 are given in Supplementary Table 1.
Immunohistochemistry
In all patients imaging results could be compared to 
immunohistological staining for SSTR2a/5 and CXCR4 
derived from biopsies of the primary tumor (n = 6) or 
metastases (n = 4) (Figure 3). Regarding the histological 
evaluation of CXCR4 expression, 1/10 samples was 
rated “mild” (IRS 3), 6/10 “moderate” (4 IRS 4, 2 IRS 
8) and 2/10 “strongly” (1 IRS 10, 1 IRS 12) positive. The 
remaining sample (patient #5) was scored negative. In 
comparison, 5/10 samples did not show any SSTR2a/5 
expression (all IRS 0), and 5/10 were moderately (all IRS 
4) positive (Table 1). 
Immunohistological CXCR4 score did not 
correspond to the intensity of [68Ga]Pentixafor uptake 
(SUVmean, SUVmax, TBRmean, TBRmax). Interestingly, two 
patients (#2, #6) had no detectable CXCR4-expression 
by PET/CT, whereas receptor expression was maximal 
on all tumor cells (IRS 10 and 12, respectively). Patient 
Figure 3: Immunohistochemical expression of CXCR4 and somatostatin receptors 2a and 5 in SCLC. Display of two 
examples of immunohistochemical expression of CXCR4 and SSTR2a and 5, respectively. Patient #3 had his biopsy taken from a lymph 
node metastasis demonstrating a weak staining for CXCR4 in 90% of the tumor cells (IRS 4). SSTR2a was negative, SSTR5 could also 
be demonstrated to be weakly expressed in 90% (IRS 4). Patient #9 also presented with extensive disease. Biopsy of the primary tumor 
revealed mild CXCR4 (intensity 1+ in 70% of the cells, IRS 3) and mild SSTR2a (intensity 1+ in 90%; IRS 4) expression. SSTR5 was 
negative in the sample.The inserts depict maximum intensity projections are the respective whole-body [68Ga]Pentixafor- and SSTR-
directed PET/CT scans, respectively.
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#6 had the biopsy sample taken from a cervical lymph 
node 5 months prior to PET imaging and received 4 
cycles of carboplatin and etoposide in the interim; 
patient #2 had started radio-chemotherapy 14 days 
prior to PET-imaging. The other patient receiving 
chemotherapy (patient #5, therapy initiated 9 days prior 
to PET imaging) presented with negative histology 
for CXCR4 but positive [68Ga]Pentixafor-PET. 
DISCUSSION
This is the first report of in vivo imaging of CXCR4 
expression in humans with both newly diagnosed as well 
as pre-treated, recurrent SCLC. A recent report evaluating 
biopsy samples of bronchopulmonary neuroendocrine 
tumors demonstrated a high intensity of CXCR4 receptor 
expression in SCLC. Additionally, chemokine receptor 
expression was a predictor of poor overall survival [11]. 
In concordance, moderate to high receptor density on the 
cell surface was visualized by PET/CT in our cohort in the 
vast majority of cases. 
Of note, in comparison to [18F]FDG-PET/CT 
 as reference, almost all tumor lesions proved to be 
CXCR4-positive with high tumor-to-background 
ratios, thus rendering CXCR4 a promising target for 
endoradiotherapy. Given the high relapse rate of SCLC 
after 1st line chemotherapy as well as the modest response 
rates to subsequent treatments, a new approach to the 
patient with relapsed/refractory SCLC is urgently needed. 
In addition to conventional chemotherapeutic agents 
including anthracycline-based regimes, topotecan or 
amrubicin [19], peptide receptor radionuclide therapy 
using radiolabelled somatostatin receptor ligands has 
been performed with rather modest success rates [20, 
21]. Important prerequisites to receptor-targeted therapies 
are a robust expression of the target receptor as well as a 
specific receptor binding. In our patient cohort, CXCR4-
PET/CT clearly outperformed SSTR-PET on a patient as 
well as a lesion basis, underlining the potential superiority 
of CXCR4 as a therapeutic target compared to SSTR.
Recently, a derivative of the diagnostic compound 
allowing labelling with various α- and β-emitters called 
Pentixather has been developed. Proof-of-concept for 
endoradiotherapy could be demonstrated in patients with 
advanced multiple myeloma with partial and complete 
metabolic responses [22]. Thus, further assessment of this 
promising tool in a theranostic approach is warranted. 
This pilot study has several limitations. First, only 
a limited number of patients could be included in the 
study. Second, biopsies were not always obtained on 
a short-term period compared to the time point of PET 
imaging and re-biopsies could not always be acquired. 
[68Ga]Pentixafor uptake did not seem to correlate with 
histological receptor expression, maybe due to receptor 
kinetics and internalization. Of note, receptor surface 
expression of CXCR4 seems to be a dynamic process 
which is influenced by a number of factors including 
therapeutic agents. The patient demonstrating the highest 
CXCR4 expression in her sample analyzed (patient #6) 
presented with a negative [68Ga]Pentixafor PET after 
concurrent 1st line chemotherapy. In addition, another 
patient (patient #2) with recently diagnosed SCLC also did 
not exhibit high receptor expression on PET after initiation 
of combined radio-chemotherapy two weeks earlier. 
Therefore, one might speculate that surface expression 
of CXCR4 is downregulated as a response to treatment 
in a time and dose dependent manner. In line with this 
observation is the fact that another subject (patient #5) 
showed intermediate SUV and no immunohistochemical 
CXCR4-positivity after a nine-day-duration of 
chemotherapy. While high expression of CXCR4 in SCLC 
has recently been demonstrated [11], future studies to 
further investigate therapy-induced down- and -preferably- 
up-regulation of CXCR4 are warranted. Potentially a 
sequential combination with chemotherapeutic agents 
with might lead to improved efficacy of CXCR4-directed 
endoradiotherapy.
Table 1: Patients' characteristics
All patients with relapsed disease had undergone 1st- and/or 2nd-line treatment (patients #1, #3, #9). 1st-line treatment included 
2-6 cycles of platinum/etoposide-containing chemotherapy (patient #1: 2 cycles, patients #3 and #9: 4 cycles, patients #4, 
#6, #7 and #8: 6 cycles) (+radiotherapy), 2nd-line therapy had topotecan as the mainstay (all three patients [#1, #3 and #9] 
received 6 cycles). 
Bx = biopsy; CTx = chemotherapy; IRS = immunoreactive score; LCNEC = large cell neuroendocrine carcinoma of the lung; 
LN = lymph node; N/A = not assessed; PD= primary diagnosis; RCTx = radio-chemotherapy; SCLC= small cell lung cancer; 
Tx = treatment.
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In conclusion, our data demonstrate the feasibility of 
[68Ga]Pentixafor for PET imaging of CXCR4 chemokine 
receptor expression in SCLC patients. This novel PET 
tracer might serve as an innovative imaging agent for in 
vivo biomarker identification that could result in patient 
selection for CXCR4-directed treatment, and, eventually, 
for receptor-radio(drug)peptide therapy.
MATERIALS AND METHODS
Subjects and study design
From January to September 2015, 10 patients 
(5 males and 5 females, mean age, 62±12 years: 
range, 38-79 years) with newly diagnosed (n = 
3) or pretreated (n = 7) SCLC (n = 9) or large 
cell neuroendocrine carcinoma (LCNEC) (n = 1) 
underwent imaging with [68Ga]Pentixafor-PET. 
 Routine staging or restaging examinations included 
[18F]FDG (n = 6) or somatostatin receptor (SSTR) 
-directed PET with [68Ga]DOTATOC (n = 5; the latter for 
identification of candidates for SSTR-directed therapy). 
Patients` characteristics are given in more detail in Table 
1.
[68Ga]Pentixafor was administered on a 
compassionate use basis in compliance with §37 of the 
Declaration of Helsinki and The German Medicinal 
Products Act, AMG §13 2b and in accordance with the 
responsible regulatory body (Regierung von Oberfranken). 
The study adhered to the standards established in the 
declaration of Helsinki. All patients gave written informed 
consent prior to imaging.
Imaging
[68Ga]Pentixafor was prepared as previously 
described [23]. In short, all syntheses were performed in a 
fully automated, GMP-compliant procedure using a GRP® 
module (SCINTOMICS GmbH, Germany) equipped with 
a disposable single-use cassette kit (ABX, Germany). 
The eluate (68Ga3+ in 0.6 M HCl) of a 68Ge/68Ga-generator 
(iThemba Labs, Faure, South Africa) was transferred 
to a cation exchange cartridge, eluted with 5 N NaCl, 
added to a solution of 40 µg Pentixafor (Scintomics, 
Fürstenfeldbruck, Germany) in HEPES-buffer and heated 
for 6 minutes at 125°C. The product was immobilized on 
a SepPak C18-cartridge, washed with water und eluted 
with ethanol/water 50/50. The eluate was passed through 
a sterile filter (0.22 µm) into a sterile vial und diluted 
with phosphate buffer solution to a total volume of 15 
mL. Radiochemical purity was determined by gradient 
high performance liquid chromatography and thin-layer 
chromatography. Additionally, the product was also tested 
for ethanol content, pH, radionuclide purity, sterility, and 
endotoxins.
 [18F]FDG was synthesized in house with a 16 
MeV Cyclotron (GE PETtrace 6; GE Healthcare, 
Milwaukee, USA). [68Ga]DOTATOC was prepared using 
a modification of the method described by Breeman et al. 
[24] using a SCINTOMICS radiotracer synthesis module 
(Scintomics, Fürstenfeldbruck, Germany).
All PET scans ([18F]FDG, [68Ga]DOTATOC and 
[68Ga]Pentixafor) were performed on a dedicated PET/CT 
scanner (Siemens Biograph mCT 64; Siemens Medical 
Solutions, Germany) within two weeks. Before acquisition 
of FDG-PET scans, patients fasted for at least 6 h prior to 
injection of [18F]FDG. Blood glucose levels were < 160 
mg/dl. Prior to [68Ga]DOTATOC and [68Ga]Pentixafor 
scans, no fasting was necessary. Imaging was perfomed 
60 minutes after injection of 124 to 149 MBq (median, 
142 MBq) of [68Ga]Pentixafor, 229 to 304 MBq (median, 
297 MBq) of [18F]FDG and 120 to 164 MBq (median, 157 
MBq) of [68Ga]DOTATOC, respectively. Corresponding 
CT low-dose scans for attenuation correction were 
acquired using a low-dose protocol (20 mAs, 120 keV, 
a 512 × 512 matrix, 5 mm slice thickness, increment of 
30 mm/s, rotation time of 0.5 s, and pitch index of 0.8) 
including the base of the skull to the proximal thighs. 
Consecutively, PET emission data were acquired in three-
dimensional mode with a 200 × 200 matrix with 2-3 min 
emission time per bed position. After decay and scatter 
correction, PET data were reconstructed iteratively with 
attenuation correction using a dedicated software (Siemens 
Esoft, Siemens, Erlangen, Germany).
Image analysis
All PET scans were first visually rated by a board-
certified nuclear medicine physician in a binary visual 
fashion as positive for disease or negative for disease. 
Semi-quantitative analysis was performed for the primary 
as well as the hottest metastatic lesion. The axial PET 
image slice displaying the maximum tumor uptake was 
selected by drawing a 3D-volume of interest (VOI) 
around the whole tumor area. Tumor regions of interest 
(ROIs) were defined in 2 ways. First, a standardized 10-
mm circular region was placed over the area with the 
peak activity. This first ROI was used to derive maximum 
(SUVmax) and mean standardized uptake values (SUVmean). 
A reference region was defined by drawing a ROI 
(diameter of 50 mm) involving normal liver parenchyma 
to derive tumor-to-background ratios. Both primary-to-
background (P/B) as well as metastasis-to-background 
(M/B) ratios for SUVmax and SUVmean were calculated. The 
radiotracer concentration in the ROIs was normalized to 




Immunohistochemistry was carried out on 10% 
formalin fixed paraffin embedded tissue sections (3µm) 
according to established protocols and scored as described 
previously (13). CXCR4-immunohistochemistry was 
performed using an anti-CXCR4 rabbit polyclonal 
antibody (ab2074; Abcam, Cambridge, UK) followed by 
detection with the DAKO en vision system according to 
the manufacturer′s protocol.
For assessment of SSTR expression, polyclonal 
antibodies against SSTR2A (1:500, RBK 046-05, 
Zytomed, Berlin, Germany) and SSTR5 (1:500, RBK 
051-05, Zytomed, Berlin, Germany) were used. Samples 
from normal pancreatic tissue were used as positive 
control (islet cells). Dewaxed samples were pretreated 
with citrate buffer pH 6.0 for 10 minutes (for SSTR2a 
staining) or with the antigen retrieval agent TIRS-EDTA 
pH 9.0, respectively, for 10 minutes in a high pressure 
cooker (for SSTR5 staining). All immunostained sections 
were counterstained for 3 minutes with hematoxylin. 
The analysis of the stained sections was done semi-
quantitatively by light-microscopy according to the 
immunoreactive score (IRS) by Remmele and Stegner 
[25]. The percentage of CXCR4-/SSTR-positive cells 
was scored as follows: 0 (no positive cells), 1 ( < 10% 
positive cells), 2 (10-50% positive cells), 3 ( > 50-80% 
positive cells), 4 ( > 80% positive cells). Additionally, the 
intensity of staining was graded: 0 (no color reaction), 1 
(mild reaction), 2 (moderate reaction), 3 (intense reaction). 
Multiplication of both scores for a given sample yields 
the IRS classification: 0-1 (negative), 2-3 (mild), 4-8 
(moderate), 9-12 strongly positive. 
Statistical analysis
Most of the data are descriptive. Statistical analyses 
were performed using IBM SPSS (version 22.0; SPSS, 
Inc. Chicago, IL). Quantitative values were expressed 
as mean ± standard deviation or median and range as 
appropriate. Comparisons of related metric measurements 
were performed using Mann-Whitney-U test. A p-value 
< 0.05 was considered to indicate statistical significance. 
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